Dangerous Drugs Menu

Receive a Free
Legal Consultation

  • This field is for validation purposes and should be left unchanged.

Please note: the information on this page is provided for informational purposes only. As of 2011, Simmons Hanly Conroy is no longer accepting cases involving Trasylol.

Trasylol is a protease inhibitor meant to reduce inflammation during bypass surgery. The drug’s purpose is to aid in reducing blood loss and the need for blood transfusions. Specifically, it is a protein administered by injection to reduce bleeding during complex surgery. Trasylol is manufactured by Bayer AG.

This medication has been used in nearly one-third of all open heart surgeries in the United States since 1993. Unfortunately, numerous studies have revealed that Trasylol puts such patients at a higher risk of death. An analysis of patients treated with the drug suggests that Trasylol could also increase the likelihood of serious kidney damage, congestive heart failure and stroke.

Health Complications and Trasylol Lawsuits

Both moderate and serious side effects have been associated with the use of Trasylol. These include:

  • Constipation
  • Diarrhea
  • Infection (fever, chills, sore throat)
  • Light-headedness
  • Vomiting
  • Severe allergic reactions (hives, itching, difficulty breathing, swelling)
  • Asthma
  • Chest pain
  • Fast or irregular heartbeat
  • Lung disorder
  • Severe stomach pain
  • Severe headaches
  • Fainting
  • Vision or speech changes

In November 2007, Bayer suspended the marketing of this drug pending final results of the BART study. When the results from the study were revealed, they showed an increase in the risk of death with Trasylol compared to aminocaproic acid and tranexamic acid.

In May 2008, the manufacturer of the medication notified the FDA of their intent to remove all remaining supplies of Trasylol from hospital pharmacies and warehouses.

Shareholder David Miceli

Shareholder David Miceli

Since 2011, Simmons Hanly Conroy no longer accepts Trasylol cases. Learn more about past litigation areas of the pharmaceutical lawyers at the firm, or explore more information on our current areas of litigation. Please contact us with any questions.

Shareholder David Miceli served on the Plaintiff’s Steering Committee for the Trasylol MDL, including a leading role in both corporate factual and expert discovery.

Client Testimonials

I am very pleased and had a wonderful experience with the firm. Would definitely use their services again.

View More Testimonials

- Margaret

204 queries. 0.993 seconds